HIKAL Hikal Q4 FY25 results (Jan–Mar 2025) and concall
Hikal reported a strong Q4 FY25 performance driven by operational leverage and cost initiatives, with significant EBITDA growth and margin expansion. The Pharma business is poised for continued growth in FY26, while the Crop Protection segment is expected to remain flat before resuming growth in FY27 due to ongoing market headwinds. The company is investing in new capabilities, R&D, and expanding its CDMO pipeline.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 453 | 448 | 552 |
| EBITDA | 75 | 72 | 123 |
| Net profit | 18 | 17 | 50 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
